Intellia Therapeutics (NTLA) Total Liabilities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Total Liabilities data on file, last reported at $137.8 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 33.17% year-over-year to $137.8 million in Q1 2026; TTM through Mar 2026 was $137.8 million, a 33.17% decrease from a year earlier, with the FY2025 full-year figure at $170.7 million, down 46.49% from the prior year.
• Total Liabilities for Q1 2026 stood at $137.8 million, down from $170.7 million in the prior quarter.
• Over the last five years, Total Liabilities for NTLA reached as high as $1.4 billion in Q1 2023 and fell as low as $137.8 million in Q1 2026.
• Historically, Total Liabilities has averaged $513.5 million across 5 years, with a median of $223.5 million in 2024.
• Across the five-year window, Total Liabilities surged 67.78% in 2022 and tumbled 84.24% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $284.5 million in 2022, then dropped by 11.85% to $250.8 million in 2023, then rose by 27.21% to $319.1 million in 2024, then plunged by 46.49% to $170.7 million in 2025, then decreased by 19.27% to $137.8 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $137.8 million in Q1 2026, $170.7 million in Q4 2025, and $176.9 million in Q3 2025.